$3 billion starter fuel for Altos Labs
Altos Labs has officially launched in California in the US and Cambridge in the UK – fuelled by $3 billion investment capital committed from global backers – its vision to transform medicine through cellular rejuvenation programming.
Altos has been fashioned as a community of leading scientists, clinicians and leaders from academia and industry working towards a common goal and the board and advisory team are rammed with Nobel Laureates and scientific leaders.
The new biotech company is dedicated to unraveling the deep biology of cellular rejuvenation programming – to restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life.
Altos has operations in the San Francisco Bay Area and San Diego, as well as Cambridge – with significant collaborations in Japan.
Set within these geographies, activity will be organised across the Institutes of Science and the Institute of Medicine. The Altos Institutes of Science will pursue deep scientific questions and integrate their findings into one collaborative research effort.
The Altos Institute of Medicine will capture knowledge generated about cell health and programming to develop transformative medicines.
The three Altos Institutes of Science will be led by Juan Carlos Izpisua Belmonte, Wolf Reik and Peter Walter. Thore Graepel will serve as global head of computational science, artificial intelligence, and machine learning.
Dr Reik, who leads The Altos Cambridge (UK) Institute of Science is a leader in epigenetic reprogramming of mammalian cells, honorary professor of Epigenetics at the University of Cambridge, and served most recently as director of the Babraham Institute in Cambridge.
He received the Wellcome Prize in Physiology and is a member of the European Molecular Biology Organisation and the Academia Europaea, a Fellow of the Academy of Medical Sciences and of the Royal Society.